A lab-made peptide that switches on the body's tissue-repair pathway, without the blood-thickening effects of the hormone it's based on (EPO).
Nerve pain and nerve repair, especially in sarcoidosis-related neuropathy.
One solid human trial exists — but only for one specific condition. Broader use is still unproven.
What it is
ARA-290 was designed to access the tissue-repair side of a hormone most people know for something else entirely: erythropoietin, or EPO. EPO is naturally produced by your kidneys and tells your bone marrow to make more red blood cells. But EPO also activates a second, separate receptor — called the Innate Repair Receptor — that triggers tissue protection and repair. ARA-290 was engineered to activate only that repair receptor, leaving the red blood cell pathway alone. That selectivity is what makes it interesting: you get the healing signal without the cardiovascular risks associated with EPO itself. It completed a Phase 2 randomized controlled trial — a real human study with a placebo comparison — for a specific type of nerve damage called sarcoidosis-related small fiber neuropathy. That trial showed not just reduced pain, but actual measurable improvement in nerve fiber density, meaning the nerves themselves were regenerating. It also has FDA Orphan Drug Designation for that indication.
Potential benefits
Neuropathic Pain — Strongest Human Evidence
Phase 2 RCT in sarcoidosis-related small fiber neuropathy showed significant pain reduction vs. placebo. Most credible human evidence of any peptide for this application.
Nerve Regeneration
Same trial showed objective improvement in corneal nerve fiber density — actual structural repair, not symptom masking. Notable finding.
Anti-Inflammatory
Activates IRR → reduces pro-inflammatory cytokines. Shown in animal models and cell culture.
Metabolic / Insulin Sensitivity
Early human data in diabetic neuropathy patients suggests metabolic benefit. Not established as standalone metabolic therapy.
Risks and contraindications
Side Effects (from clinical trials)
- Injection site reactions — most common adverse event
- Transient flu-like symptoms — mild, self-resolving
- Headache · Fatigue
Theoretical Risks
- Long-term IRR activation effects unknown beyond trial duration
- EPO-pathway origin — cancer populations warrant caution
- Interactions with immunosuppressants not characterized
- Off-target receptor effects at higher/longer doses not ruled out
Contraindications / cautions
- Active cancer or cancer history (EPO-pathway caution)
- Pregnancy · Breastfeeding · Under 18
- Organ transplant recipients on immunosuppression
- Known hypersensitivity to EPO-derived compounds
Research reality
Neuroprotection, anti-inflammatory effects, and tissue repair have been demonstrated across multiple animal models. The mechanism is well-described at the molecular level, giving the preclinical foundation real scientific credibility.
A Phase 2 randomized controlled trial showed both significant pain reduction and objective nerve regeneration in sarcoidosis-related small fiber neuropathy. Finding actual structural repair — not just symptom improvement — in a human trial is notable. Phase 3 confirmation hasn't been completed yet.
Long-term safety data doesn't exist beyond the trial duration, which was weeks to months. The short-term profile from the trial is encouraging — no major safety signals emerged. The FDA Orphan Drug Designation reflects the rare-disease research status, not formal approval.
One of the most scientifically credible peptides in this guide for neuropathic pain. The RCT showing structural nerve repair is meaningful. The strongest evidence is for sarcoidosis-related neuropathy specifically — other uses extrapolate beyond that data. If you have cancer-risk factors, we'd screen carefully first.